Libre by Abbott vs epocrates: Drug Info & Pill ID
Revenue, downloads, ratings and category context for two iOS apps. Figures are estimates and should be read as ranges, not exact totals.
Libre by AbbottAbbott Labs - Medical
epocrates: Drug Info & Pill IDEpocrates - Medical| Metric | Libre by Abbott | epocrates: Drug Info & Pill ID | Readout |
|---|---|---|---|
| Estimated revenue / mo | $*** - opens with trial | $*** - opens with trial | Partial signal |
| Revenue band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Estimated downloads / mo | $*** - opens with trial | $*** - opens with trial | Libre by Abbott |
| Download band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Rating | 4.58 | 4.44 | Libre by Abbott |
| Rating count | 181k | 7.1k | Libre by Abbott |
| Tracked keywords | — | 1 | epocrates: Drug Info & Pill ID |
| Category | Medical | Medical | Same market |
Which app is bigger?
Libre by Abbott and epocrates: Drug Info & Pill ID are compared inside Medical with monthly revenue, downloads, rating, review volume, keyword footprint, category placement and range context. Libre by Abbott leads on monthly downloads in the current readout, while a clean revenue readout is available only for epocrates: Drug Info & Pill ID in this pair. Libre by Abbott wins demand, Libre by Abbott has deeper review volume, and epocrates: Drug Info & Pill ID has the larger tracked keyword footprint. The better app depends on the job: choose the revenue leader when you need monetization proof, choose the download leader when reach matters, and choose the higher-rated or deeper-reviewed app when market trust is the constraint. Read both ranges rather than only the midpoint, then open the category hub and related collections to see whether this pair is an outlier or a normal category pattern.